Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiron and Xoma begin leukemia trials
CHIR-12.12, a fully human, antagonist antibody that targets the CD40 antigen, is the first drug candidate to enter clinical testing under the collaborative agreement between Chiron and Xoma,
CHIR-12.12, a fully human, antagonist antibody that targets the CD40 antigen, is the first drug candidate to enter clinical testing under the collaborative agreement between Chiron and Xoma,
GelStat Arthritis is the company’s second over-the-counter (OTC) product and, like GelStat Migraine, utilizes the company’s patent pending formulation in combination with a sublingual (under the tongue) delivery
A total of 84,940 new shares of OSI Pharmaceuticals were issued in exchange for the 286,200 minority interest shares of Prosidion, which represents 2.7% of Prosidion shares. The
The primary purpose of the phase I clinical trial was to determine the safety, maximum tolerated dose, dose-limiting toxicities, and pharmacokinetics of HGS-ETR1 in patients with relapsed or
The preclinical studies were conducted in a melanoma mouse model, which is commonly used to evaluate experimental cancer treatments. Mice were treated with an experimental version of the
Corgentech’s novel cancer therapy, HIF Decoy, is a high affinity, specific inhibitor of both HIF-1 and HIF-2, transcription factors that play key roles in cancer cell growth, survival
The ongoing clinical trial is an open label, multi-center, sequential group dose escalation study designed to assess the safety and antiviral activity of ANA380 in chronically infected HBV
Ranexa (ranolazine) was well tolerated in the study, named ERICA, and there were no cases of syncope (fainting). Under the trial’s special protocol assessment (SPA) process agreement, these
Results from the first treatment phase of the EPIC(3) trial, a major ongoing study, have shown that a significant portion of patients chronically infected with hepatitis C virus
A poster presentation at the 96th annual meeting of the American Association for Cancer Research (AACR) in California, reviewed the results of a study designed to explore the